Previous 10 | Next 10 |
home / stock / esaly / esaly news
AbbVie, Eisai, and EA Pharma Launch "Humira Support Tool Ordering Service for Patients" TOKYO, Sept 13, 2021 - (JCN Newswire) - AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd. announced today that, on September 13, 2021, the companies launched "Humira Support Tool Ordering...
With Labor Day marking the unofficial end of summer, September looks to be a busy month for events impacting pharmaceutical and biotechnology companies. Here's a look at what events to look forward to this month that could impact pharma and biotech stocks. Sept. 3: FDA Cellular, Tissue,...
Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in Five ASEAN Countries TOKYO, Aug 31, 2021 - (JCN Newswire) - Eisai Co., Ltd. and FUJI YAKUHIN CO., LTD. announced today that th...
Merck & Co. (NYSE: MRK) announced earlier this month that its blockbuster cancer drug Keytruda was approved by the U.S. Food and Drug Administration (FDA) in combination with Eisai 's (OTC: ESALY) Lenvima to treat advanced renal cell carcinoma (RCC, also known as kidney ...
Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Launched in Japan for EZH2 Gene Mutation-Positive Follicular Lymphoma TOKYO, Aug 16, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has launched the anticancer agent EZH2 inhibitor "Tazverik...
FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for First-Line Treatment of Adult Patients with Advanced Renal Cell Carcinoma (RCC) TOKYO and KENILWORTH, N.J., Aug 12, 2021 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A....
Eisai Co., Ltd. (ESALF) Q1 2022 Earnings Conference Call August 04, 2021 03:00 AM ET Company Participants Ryohei Yanagi - Executive Vice President & Chief Financial Officer Ivan Cheung - Senior Vice President & President of Neurology Business Group Terushige Iike - Senior Vice Preside...
Eisai Receives Award for Excellence in Corporate Communications at the 37th Corporate Communications Awards TOKYO, Aug 5, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received the Award for Excellence in Corporate Communications at the 37th annual Corpor...
The inspector general at the U.S. Department of Health and Human Services (HHS) is set to review how the FDA implements its accelerated approval pathway nearly two months after the approval of controversial Alzheimer’s drug Aduhelm developed by Biogen (BIIB +0.2%) with Eisai (OTCPK:ESA...
Eisai (OTCPK:ESALY -1.4%) will "seek the most optimal and expedited regulatory pathway forward for lecanemab," an Alzheimer's candidate under development with Biogen (BIIB -0.2%), according to Ivan Cheung, Eisai's (OTCPK:ESALF) head of neurology. Cheung made the comments today during the comp...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co. Ltd. ADR Company Name:
ESALY Stock Symbol:
OTCMKTS Market:
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria and Commitment for Funding to the 3rd Phase of Global Health Innovative Technology Fund Activities TOKYO, May 25, 2023 - (JCN Newswire) - Eisai Co., Ltd. has announced that it will grant a t...
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 TOKYO, May 24, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline durin...
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., May 16, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (b...